![](https://monteverdelaw.com/wp-content/uploads/case-logo/kinnate-biopharma-inc.png)
Kinnate Biopharma Inc. (Nasdaq: KNTE), relating to its proposed sale to XOMA Corp. Under the terms of the agreement, KNTE shareholders are expected to receive $2.3352 in cash plus an additional cash amount not exceeding $0.2527 per share they own.
Kinnate Biopharma Inc. (Nasdaq: KNTE), relating to its proposed sale to XOMA Corp. Under the terms of the agreement, KNTE shareholders are expected to receive $2.3352 in cash plus an additional cash amount not exceeding $0.2527 per share they own.